Tempest Therapeutics Secures $2.0M in Private Placement, Potentially $6.0M with Warrants
TPST is trading near its 52-week low of $2.12 (5.6% above the low) on elevated volume (2.8× avg).
Summary
Tempest Therapeutics entered into a private placement agreement to raise $2.0 million initially, with the potential for an additional $4.0 million upon warrant exercise, to fund working capital and general corporate purposes.
Key Events · Financing and Capital Events · TPST
-
Private Placement Agreement
Tempest Therapeutics entered into a securities purchase agreement on March 20, 2026, for a private placement with two institutional investors and a strategic investor.
-
Initial Capital Raise
The company expects to receive approximately $2.0 million in gross proceeds from the sale of 462,964 shares of common stock and up to 462,963 pre-funded warrants.
-
Potential Additional Funding
Up to an additional $4.0 million in gross proceeds may be received in the future upon the cash exercise of accompanying Series A and Series B warrants.
-
Securities Issued
The offering includes common stock, pre-funded warrants (exercisable at $0.001 per share), and 1,851,854 common warrants (exercisable at $2.16 per share).
Analysis · TPST · Life Sciences
This financing event provides Tempest Therapeutics with crucial capital, addressing immediate working capital needs for this nano-cap life sciences company. While the offering involves significant potential dilution through the issuance of common stock and warrants, the initial $2.0 million raise, with a potential total of $6.0 million, is substantial relative to the company's market capitalization. The pricing of the shares and warrants is close to the current market price, which is a more favorable term than deep discount offerings often seen in distressed situations. The requirement for stockholder approval for the common warrants introduces a future contingency, but the company's commitment to seeking it is noted. Investors should monitor the outcome of the stockholder vote and the subsequent exercise of warrants, as full exercise would significantly increase the outstanding share count.
At the time of this filing, TPST was trading at $2.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.9M. The 52-week trading range was $2.12 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.